Research

Sponsor: REGENXBIO Inc.- ALTITUDE A Phase 2, Randomized, Dose-escalation, Observation-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of RGX-314 Gene Therapy Delivered via a Single Suprachoroidal Space (SCS) Injection in Participants with Diabetic Retinopathy (DR) Without Center Involved-Diabetic Macular Edema.

KODIAK GLOW 2 (KS301P108) A Prospective, Randomized, Double-masked, Sham-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tarcocimab Tedromer in Participants with Diabetic Retinopathy (DR).

Sponsor: Oculis Sarl Operations- DX221 A Phase 3 Double-masked, Randomized, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema.

Diamond trial, a drop used to treat Diabetic Macular Edema

Sponsor: RegenexBio ATMOSPHERE a randomized partially masked controlled clinical study to evaluate the efficacy and safety of RGX-314 Gene Therapy in participants with nAMD. Lucentis

Sponsor: RegenxBio ASCENT a randomized partially masked controlled clinical study to evaluate the efficacy and safety of RGX-314 Gene Therapy in participants with nAMD. Eyela

Sponsor: AbbVie Inc.- RGX-314-5101 A Long-term Follow-Up Study to Evaluate the Safety and Efficacy of RGX-314 Following Subretinal Administration in Participants with Neovascular Age-related Macular Degeneration and Fellow Eye Treatment Substudy.

SOL-1(OTX-TKI-2023-AM-301) A Phase 3, Multicenter, Double-Masked, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration.

SOL-R (OTX-TKI-2023-AMD-303) A Phase 3, Multicenter, Double-Masked, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration.

EyePoint (EYP-1901-302) A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects with Wet AMD.

KODIAK DAYBREAK (KS301P109): A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Three-arm Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tarcocimab Tedromer and Tabirafusp Tedromer Compared with Intravitreal Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD).

Geographic Atrophy Sponsor: ORA Cognition Therapeutics (PILL STUDY) A Randomized, Double-Masked, Placebo-controlled, Parallel group, Phrase 2 Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants with Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).

Sponsor: i-Lumen Scientific, Inc.- i-SIGHT Microcurrent stimulation therapy for nonexudative age-related macular degeneration: a multicenter, randomized, sham-controlled, feasibility device trial.

SIENNA (R3918-AMD-2326): A multicenter, randomized, double-masked, placebo-controlled phase 3 study of the efficacy, safety, and tolerability of subcutaneously administered pozelimab in combination with cemdisiran or cemdisiran alone in participants with geographic atrophy secondary to age-related macular degeneration.

Sponsor: KODIAK GLEAM A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME)

ETA: CLOSED

Sponsor: KODIAK GLOW A Prospective, Randomized, Double-masked, Active Comparatorcontrolled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME)

ETA: CLOSED

Sponsor: ORA ANX007-GA-0 A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Masked, 4-Arm, Sham-Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) Geographic Atrophy (GA)

ETA: CLOSED

Sponsor: KODIAK Daylight A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD) (DAYLIGHT)

ETA: CLOSED

Sponsor: OcuTerra-OTT 166-201 DREAM OTT166-201 A Phase 2 Randomized, Double-Masked, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of OTT166 Ophthalmic Solution in the Treatment of Diabetic Retinopathy (DR)

ETA: CLOSED

Sponsor: Opthea OPT-302-1005 COAST Eyelea OPT-302-1005-COAST A Phase 3, Multicentre, Double-masked, Randomized Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)

ETA: CLOSED

VGFTe-HD-RVO-2335: A Phase 3 randomized, double-masked, active-controlled study of the efficacy and safety of 8 mg Aflibercept in participants with Macular Edema following Retinal Vein Occlusions.

ETA: CLOSED